ORGANIZATION

• JPMA Keen to Defend R&D Tax Credit System
  July 8, 2016

• Generic Use Rate at 55.7% in FY2015, Up 3.7 Points: JGA
  July 8, 2016

• EFPIA Japan Calls for Diversifying Vaccine Supply Sources to Prepare for Crises
  July 7, 2016

• Drug Damage Watchdog Challenges Doctors’ View, Says HPV Vaccination Shouldn’t Be Recommended
  July 5, 2016

• JMA Vice President Nakagawa Calls for Rules on Use of “Expensive Drugs”
  June 27, 2016

• Yokokura Reelected for Third Term as JMA President
  June 27, 2016

• NPO Asks MHLW to Take Steps to Ensure Proper Use of Xeplion
  June 23, 2016

• PMDA Chief Brings Together Drug Makers, Tech Vendors to Compile Proposal on Digital Health
  June 17, 2016

• Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
  June 14, 2016

• FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
  June 14, 2016

• Reimbursement Prices Kept Unchanged for Over 20% of Drugs: FPMAJ Survey
  June 13, 2016

• FPMAJ Wants to Avoid Narrowing-Down of Premium-Eligible Products: Kamoya
  June 13, 2016

• FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
  June 13, 2016

• 9 Pharma-Related Companies to Join to Global Health Innovative Technology Fund
  June 8, 2016

• Japan Is at Crossroads, Must Carry On Its Pro-Innovation Policies: PhRMA Chairman
  June 3, 2016

• PhRMA Still “Concerned” about Anti-Innovation Policies despite Tax Decision: Japan Chief
  June 2, 2016

• Biosimilar Policies Shouldn’t Threaten Biologics Development: EFPIA Japan
  May 31, 2016

• Astellas’s Hatanaka Elected as New JPMA President
  May 27, 2016

• Sumitomo Dainippon Pres. Tada Picked as New Chief of FPMAJ
  May 27, 2016

• No Need to Add Hep B Vaccines to Public Immunization Program: Drug Damage Watchdog
  May 13, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 48
• 49
• 50
• 51
• 52
• 53
• 54
• 55
• 56
• …
• Next ›
• 最終 »